The Ebola virus breakout in Western Africa dominated a lot of the reports in 2014. The highly communicable pathogen spreads swiftly and kills over half of those people who become infected, resulting in major panics across multiple continents. While the vast majority of the dead are in Africa, health workers did bring the virus home to other nations and continents.
For all the doom and gloom and focus upon doomsday scenarios on what the pathogen could do, there are basically dome economic benefits of Ebola virus break outs. The economic benefits mostly breakdown between nonprofit or govt groups and for-profit biotechnology corporations.
Central authority or help organizations like the Red Cross or the CDC have a tendency to see increases in funding in events like these. The industrial benefits to them are direct and help out those on the ground suffering or assisting and containing an outburst.
This containment keeps commercial interruption when funding is satisfactory to turn the tide of an onset.
The long term commercial benefits of Ebola virus outbreaks are biotech companies working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medicinal compounds prove to be of worth.
While the 2014 Ebola break out is the first to have caught world attention as much as it did, it was hardly the first onset. Others have occurred, and more will happen in the future. Any business that has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in future times.
For all the doom and gloom and focus upon doomsday scenarios on what the pathogen could do, there are basically dome economic benefits of Ebola virus break outs. The economic benefits mostly breakdown between nonprofit or govt groups and for-profit biotechnology corporations.
Central authority or help organizations like the Red Cross or the CDC have a tendency to see increases in funding in events like these. The industrial benefits to them are direct and help out those on the ground suffering or assisting and containing an outburst.
This containment keeps commercial interruption when funding is satisfactory to turn the tide of an onset.
The long term commercial benefits of Ebola virus outbreaks are biotech companies working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medicinal compounds prove to be of worth.
While the 2014 Ebola break out is the first to have caught world attention as much as it did, it was hardly the first onset. Others have occurred, and more will happen in the future. Any business that has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in future times.
About the Author:
my name is alfred obi I've been a biological scientist for years educating individuals on ebola virus disease update and ebola virus disease which has influenced most nations in africa feel free to visit my site for your free protecting gear on ebola thanks.
